Dr Helga Einarsdóttir joins Akthelia Pharma as R&D Program Manager for Wound Therapeutics
REYKJAVIK, Iceland -- 26 October, 2023 -- Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, is pleased to announce the appointment of Dr Helga Einarsdóttir as R&D Program Manager for Wound Therapeutics.
Helga previously held the position of Senior Researcher at Kerecis and prior to that was a postdoctoral researcher at the Immunology department at the Landsspítali University Hospital in Iceland.
"I am delighted to welcome Helga to our growing team" commented Egill Masson, CEO of Akthelia Pharma, "Her background in immunology is particularly relevant as Akthelia continues to develop and expand its world-leading epithelial immunomodulatory platform."
Helga has extensive experience of regulatory submissions and pre-clinical and clinical trials and her background in immunology is particularly relevant as Akthelia continues to develop and expand its epithelial immunomodulatory platform.
Helga has a PhD in immunology from the University of Amsterdam and is a certified FELASA Animal Laboratory Science expert.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.
Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.
Egill Masson CEO firstname.lastname@example.org
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland